Sign in

NCT03284593Active, not recruiting

Prognostic Factors and the Impact of Various Management of Acute Myeloid Leukemia in Real Life Condition

Prognostic Factors and the Impact of Various Management of Acute Myeloid Leukemia in Real Life Condition at Toulouse and Bordeaux University Hospital

Source: ClinicalTrials.gov · Last updated 30 Jul 2020

Brief summary (registry, in English)

The treatment of older patients with acute myeloid leukemia that is secondary to previous myelodysplastic syndrome, myeloproliferative neoplasm, or prior cytotoxic exposure remains unsatisfactory. We compared patients treated with intensive chemotherapy or azacitidine within two centres.

Status (registry)
Active, not recruiting
Study type
Observational
Enrollment
199 (actual)
First submitted
13 Sept 2017
Start date
1 Dec 2014
Primary completion date
31 Dec 2030
Lead sponsor
University Hospital, Toulouse
NCT number
NCT03284593

What you commit to

  • Study type: Observational
  • Participants enrolled: 199
  • From 1 Dec 2014 to the primary completion date, 31 Dec 2030
  • 2 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

  • patients with acute myeloid leukemia

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (2)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
University Hospital Bordeaux
Coordinator of this site? Confirm its status
BordeauxFranceUnknown status
University Hospital, Toulouse
Coordinator of this site? Confirm its status
ToulouseFranceUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.